未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial
Dong, Baiqiang; Chen, Long; Pang, Qingsong; Jiang, Ou; Ge, Hong; Cheng, Yufeng; Zhou, Rongrong; Meng, Xiangjiao; Li, Jie; Zhu, Xuan; Wang, Xunqiang; Cao, Qiuyue; Ji, Yongling; Chen, Ming 分享 收藏 AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)Gong, Youling; Pang, Qingsong; Yu, Rong; Zhu, Zhengfei; Huang, Jiangqiong; Cheng, Yufeng; Zhong, Diansheng; Wu, Hongbo; Yoo, Seung Soo; Dobbs, Tracy; Bao, Zinan; Zuo, Yunxia; Wei, Boxian; Sun, Pu; Lu, You 分享 收藏 分享 收藏 分享 收藏 Efficacy of anti-programmed cell death protein 1 monoclonal antibody combined with bevacizumab and/or Pseudomonas aeruginosa injection in transplanted tumor of mouse forestomach carcinoma cell gastric cancer in mice and its mechanism in regulating tumor immune microenvironmentLiu, Xiangyong; Yan, Chao; Yang, Aijie; Yu, Enhao; Yu, Jie; Zhou, Chunyang; Wang, Yun; Wang, Kai; Sun, Ying; Cheng, Yufeng 分享 收藏 Envonalkib vs crizotinib in treatment-naive advanced ALKpositive NSCLC: A randomized, multicenter, phase III trialZhang, L.; Fang, W.; Min, J.; Yang, N.; Yu, Q.; Cheng, Y.; Zhao, Y.; Li, M.; Chen, H.; Ren, S.; Zhou, J.; Zhuang, W.; Qin, X.; Cao, L.; Yu, Y.; Zhang, J.; He, J.; Feng, J.; Yu, H. 分享 收藏 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive advanced ALK plus non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA studyZhou, C.; Lu, Y.; Kim, S-W.; Baisamut (Reungwetwattana), T.; Zhou, J.; Zhang, Y.; He, J.; Yang, J.; Cheng, Y.; Lee, S-H.; Chang, J.; Fang, J.; Liu, Z.; Bu, L.; Qian, L.; Xu, T.; Archer, V.; Hilton, M.; Zhou, M.; Zhang, L. 分享 收藏 A mutational signature for colorectal cancer prognosis prediction: Associated with immune cell infiltrationXu, Liang; Lin, Yanyun; Chen, Xijie; Zheng, Lisheng; Cheng, Yufeng; Hu, Jiancong; Zheng, Bin; Zhang, Bin; Li, Guanman; Chi, Zengjie; Guo, Shuang; Liu, Danling; He, Xiaosheng; Lan, Ping 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Monocarboxylate transporter 1 is an independent prognostic factor in esophageal squamous cell carcinoma单羧酸转运蛋白1是食管鳞状细胞癌的独立预后因素Chen, Xue; Chen, Xuan; Liu, Fang; Yuan, Qianqian; Zhang, Kaixian; Zhou, Wei; Guan, Shanghui; Wang, Yuanyuan; Mi, Si; Cheng, Yufeng 分享 收藏 分享 收藏 分享 收藏 Low expression of BEX1 predicts poor prognosis in patients with esophageal squamous cell cancerGeng, Hai-Tao; Cheng, Zhi-Wen; Cao, Rui-Juan; Wang, Zhen-Bo; Xing, Shao-Zhi; Guo, Chen; Wang, Feng; Liu, Chang-Min; Chen, Shao-Shui; Cheng, Yu-Feng 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
CANCER RESEARCH.png)
